United Kingdom Dysphagia Management Industry Outlook for (2023 and 2033)

The United Kingdom's dysphagia management business revenue is expected to increase from US$ 232.4 million in 2023 to US$ 293.3 million by 2033. Over the forecast period, demand for dysphagia management products across the United Kingdom is predicted to rise at a CAGR of 2.4%. Total revenue from the dysphagia management business in the United Kingdom totaled US$ 228.2 million at the end of 2022.

The rising prevalence of neurological disorders, structural abnormalities, or other medical conditions is expected to push the cases of dysphagia worldwide. The growing need for treating this condition is expected to drive the demand for dysphagia management solutions.

Key companies are focusing on developing new drugs and medical devices for the management of swallowing disorders in the United Kingdom. This is expected to foster growth in the United Kingdom’s dysphagia management business.

Other Factors Driving Dysphagia Management Demand in the United Kingdom-

  • Development of cutting-edge dysphagia management tools in the United Kingdom
  • Easy availability of dysphagia treatment and services in the United Kingdom
  • Favorable government support
  • Rising health awareness and expansion of healthcare infrastructure
Attributes Key Insights
Dysphagia Management Business Size in the United Kingdom (2022) US$ 228.2 million
Estimated United Kingdom Dysphagia Management Business Revenue (2023) US$ 232.4 million
Projected United Kingdom Dysphagia Management Business Revenue (2033) US$ 293.3 million
Value-based CAGR (2023 to 2033) 2.4%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 United Kingdom Dysphagia Management Business Vs. 2033 to 2033

The United Kingdom dysphagia management business recorded a CAGR of 1.2% from 2018 to 2022. Total revenue in the country reached US$ 228.2 million at the end of 2022. Over the assessment period, dysphagia management demand in the United Kingdom is predicted to increase at a 2.4% CAGR.

Historical CAGR (2018 to 2022) 1.2%
Forecast CAGR (2023 to 2033) 2.4%

Several factors are expected to spur growth in the United Kingdom's dysphagia management business. These include the rising prevalence of dysphagia and other swallowing disorders, growing health awareness, and increasing spending on swallowing disorder treatment in the United Kingdom.

Dysphagia is especially prevalent among the geriatric population. For instance, studies suggest that dysphagia is thought to affect around 4 million people in the United Kingdom. This will continue to drive demand for dysphagia management solutions.

Certain chronic health conditions, such as gastroesophageal reflux disease (GERD), muscular dystrophy, and scleroderma, can result in dysphagia. Hence, the increasing prevalence of these conditions is expected to create lucrative opportunities for dysphagia management companies.

In the United Kingdom, the National Health Service (NHS) and the Department of Health and Social Care are playing a key role in tackling the burden of swallowing disorders, including dysphagia. This will positively impact overall dysphagia management product sales.

For instance, the Speech and Language Therapy service at Sheffield Teaching Hospital’s NHS Foundation Trust launched a novel bite-sized online learning resource to improve the understanding of dysphagia. These initiatives are likely to boost dysphagia management solution sales.

Primary Factors Propelling United Kingdom’s Dysphagia Management Demand

Dysphagia can lead to feelings of frustration, embarrassment, and isolation. Difficulty in eating and drinking can result in a reduced quality of life, impacting an individual's social interactions and overall happiness. Hence, the importance of dysphagia management is proliferating.

Dysphagia is commonly seen in patients with neurological disorders and stroke. The main symptoms of dysphagia in neurological disorders are delayed oral transit and difficulties in bolus formation, among others. To treat this condition, patients are expected to opt for dysphagia management solutions, including PPIs, feeding devices, and nutritional supplements.

To avoid difficulties in swallowing solid foods, consumers are showing interest in dysphagia supplement products such as powder thickeners and gel thickeners. The increasing adoption of these supplements will boost the total dysphagia management business revenue.

Greater awareness about dysphagia means that healthcare professionals are more likely to identify and diagnose swallowing disorders at an early stage. This can lead to quicker interventions and better outcomes for individuals with dysphagia.

The recognition of dysphagia as a significant health concern can drive research and innovation in the field. This can lead to the development of new diagnostic tools, therapies, and products designed to improve the quality of life for individuals with dysphagia.

The increasing awareness of dysphagia in the United Kingdom and emerging countries is a positive development that can lead to better healthcare outcomes and increased access to dysphagia management services. It will also create new opportunities for innovation and collaboration in the field of dysphagia management.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Restrictive Factors in the United Kingdom Dysphagia Management Business

The usage of equipment in high-risk anatomical regions, including the anterior neck, requires specific clearance from the Food & Drug Administration (FDA). The general clearance for neuromuscular stimulation/reeducation is not sufficient. This is acting as an impediment for companies.

Contrary to other body parts, the FDA has always issued a warning label for the use of neuromuscular electrical stimulation (NMES) on the anterior neck. This is because there is a chance of severe harm or death while utilizing general clearance NMES devices and supplies on the neck. This factor is limiting the growth of the target business to a certain extent.

Long-term use of dysphagia drugs such as proton pump inhibitors is associated with certain threats, such as the increased risk of hip bone fracture. This is due to the decreased absorption of calcium and iron and the risk of opportunistic infections with S. pneumonia and C. defficile owing to diminished natural gut flora.

The use of nasogastric tubes or PEG tubes can cause irritation to the throat, which leads to severe discomfort. Long-term administration of such tubes can cause abdominal cramping, abdominal swelling, diarrhea, nausea, vomiting, and regurgitation of food and medicines.

Dysphagia drugs, such as proton pump inhibitors (PPIs) and H2 blockers, are expected to be commonly used to treat GERD, a condition that can cause dysphagia. While these drugs are generally safe and effective, they can cause side effects such as headache, diarrhea, and abdominal pain.

In a handful of cases, long-term use of PPIs has been linked to an increased risk of certain health conditions, such as bone fractures, kidney disease, and other infections. Hence, the side effects of PPIs and feeding tubes can limit their usage, thereby hampering the expansion of the target business.

Comparative View of Adjacent Businesses

The United Kingdom's dysphagia management business is expected to be impacted by the peer or tangential businesses in the healthcare division. This includes businesses such as proton pump inhibitors and throat sprays market. On analysis of these related sectors, the report has detected profound insights that will be helpful for developing unique differentiating strategies to pursue growth and opportunity.

United Kingdom Dysphagia Management Demand Outlook:

Attributes United Kingdom Dysphagia Management Demand Outlook
CAGR (2023 to 2033) 2.4%
Value (2023) US$ 293.3 million
Growth Factor The growing prevalence of dysphagia is expected to drive the demand for dysphagia management products, including drugs and feeding tubes.
Key Trend The development of new dysphagia therapies in Britain is a key trend in the dysphagia management business.

Proton Pump Inhibitor Sales Forecast:

Attributes Proton Pump Inhibitor Sales Forecast
CAGR (2023 to 2033) 5.2%
Value (2023) US$ 3.0 billion
Growth Factor Growing demand for effective acid-suppressing medication is anticipated to bolster proton pump inhibitor sales.
Key Trend The rising prevalence of gastrointestinal disorders and the development of new PPIs are key trends impacting sales.

Throat Spray Industry Analysis:

Attributes Throat Spray Industry Analysis
CAGR (2023 to 2033) 2.1%
Value (2023) US$ 484 million
Growth Factor The rising prevalence of upper respiratory tract infections is expected to drive demand for throat sprays.
Key Trend Increasing promotional and awareness campaigns will create growth prospects for throat spray manufacturers.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

State-wise Insights

Growth Outlook by Key States

States Value CAGR
Greater London 1.9%
West Midlands 2.8%
Greater Manchester 3.6%
West Yorkshire 5.7%
Glasgow 2.6%

Rising Prevalence of Dysphagia Driving Demand in Greater London

As per the latest report, Greater London is projected to remain a lucrative pocket for dysphagia management companies across England. Over the forecast period, the demand for dysphagia management solutions in Greater London is projected to rise at a 1.9% CAGR.

By 2033, Greater London’s dysphagia management business revenue is anticipated to reach US$ 46.8 million. It will likely hold a share of 21.1% in England by the end of 2033. This is attributable to the rising incidence of dysphagia.

Dysphagia often results from underlying medical conditions such as stroke, Parkinson's disease, and dementia. Greater London's diverse and growing population can experience a higher prevalence of these conditions, driving the demand for dysphagia management.

Awareness among healthcare professionals and the public regarding the diagnosis and management of dysphagia is also growing rapidly in Greater London. This can lead to early diagnosis and intervention, increasing the need for related services.

Presence of Rehabilitation Centers Boosting Revenue in West Midlands

West Midlands is projected to experience a CAGR of 2.8% during the forecast period. Total dysphagia management sales in the West Midlands are set to reach US$ 23.0 million by 2033. The presence of rehabilitation centers and long-term care facilities in the region can drive the demand for dysphagia management products and services, as these institutions often cater to patients with swallowing difficulties.

The presence of well-established healthcare infrastructure, including hospitals, clinics, and skilled healthcare professionals specializing in dysphagia management, can encourage patients to seek treatment across the region. This will boost overall revenue in the West Midlands through 2033.

Category-wise Insights

The section below shows the drugs segment witnessing a higher CAGR of 5.2% during the assessment period. Based on indication, the oropharyngeal dysphagia category is expected to hold a prominent value share by 2033, exhibiting a CAGR of 1.5%. By distribution channel, the hospital pharmacies segment will retain its dominance in the United Kingdom, thriving at a 1.2% CAGR through 2033.

Proton Pump Inhibitors to Witness High Demand in the United Kingdom

Growth Outlook by Key Product

Product Value CAGR
Drugs (Proton Pump Inhibitors) 5.2%
Feeding Tubes 1.6%
Nutritional Solutions 2.2%
Devices 4.1%

Based on product, the drugs (proton pump inhibitors) segment is expected to thrive at a 5.2% CAGR during the forecast period. As a result, dysphagia management companies looking to boost their revenue will likely shift their focus on offering novel and effective proton pump inhibitors.

Proton pump inhibitors (PPIs) are primarily prescribed to reduce stomach acid production. By managing conditions such as GERD and acid reflux, which are common causes of dysphagia, PPIs help alleviate the symptoms and underlying causes of swallowing difficulties. This, in turn, leads to better dysphagia management.

PPIs can also help reduce the discomfort associated with acid-related conditions, making it easier for individuals with dysphagia to eat and swallow. This improved comfort can lead to better patient compliance with dysphagia management plans.

Oropharyngeal Dysphagia to Generate Maximum Revenue for Companies

Growth Outlook by Indication

Indication Value CAGR
Oropharyngeal Dysphagia 1.5%
Esophageal Dysphagia 5.2%

As per the latest dysphagia management industry analysis, the oropharyngeal dysphagia segment is set to create lucrative revenue generation for dysphagia management companies. This is attributed to the rising prevalence of oropharyngeal dysphagia in the United Kingdom.

The oropharyngeal dysphagia segment is anticipated to expand at a 1.5% CAGR during the forecast period. It is expected to total US$ 218.2 million by 2033, accounting for a value share of 74.4% in the United Kingdom.

Oropharyngeal dysphagia patients frequently require speech therapy and rehabilitation to improve their swallowing function. This drives the demand for speech therapists, drugs, medical devices, and rehabilitation facilities, which are key components of the dysphagia management business.

Oropharyngeal dysphagia treatment plans are often tailored to the individual's specific needs and the underlying causes of the condition. This personalization of care can result in a variety of management options and interventions, including dietary modifications and exercises, all of which contribute to revenue growth.

Hospital Pharmacies to Retain Their Dominance Through 2033

Growth Outlook by Key End-user

Application Value CAGR
Hospital Pharmacies 1.2%
Retail Pharmacies 1.8%
Drug Stores 2.9%
Specialty Clinics 5.1%

Based on end-users, the hospital pharmacies segment is projected to expand at a 1.2% CAGR during the assessment period. As per the latest analysis of dysphagia management in the United Kingdom, the target segment will likely hold a share of about 36.2% by 2033.

Hospital pharmacies are responsible for dispensing medications to patients within the hospital. For dysphagia patients, this can include specialized oral medications or alternative routes of administration, such as enteral feeding through feeding tubes. The availability and proper management of these medications are essential for effective dysphagia treatment.

Competitive Landscape

Strategic partnerships are a priority for leading dysphagia management companies in the United Kingdom as they work to create new product lines and expand their global consumer base. Key players are also investing heavily in research and development to develop cutting-edge dysphagia management tools in the United Kingdom.

Recent Developments in the United Kingdom Dysphagia Management Business-

  • In October 2022, the United Kingdom-based company Phagenesis Ltd. launched the Phageneyx Neurostimulation System in the United States. The new system uses pharyngeal electrical stimulation to treat people with dysphagia.
  • In October 2022, Eisai and Cogstate expanded their agreement for the global development and commercialization of digital cognitive assessment technologies.
  • In December 2022, Astellas, Eisai, Daiichi Sankyo, and Takeda agreed to collaborate to reduce the environmental burden in the field of pharmaceutical packaging.

Scope of the United Kingdom Dysphagia Management Business Report

Attribute Details
Estimated Value (2023) US$ 232.4 million
Expected Value (2033) US$ 293.3 million
Anticipated Growth Rate (2023 to 2033) 2.4% CAGR
Forecast Period 2023 to 2033
Historical Data Available for 2018 to 2022
Industry Analysis US$ million for Value
Key Regions Covered England; Wales; Scotland; Northern Ireland
Key States Covered Greater London, West Midlands, Greater Manchester, West Yorkshire, Rest of England, Cardiff, Swansea, Rhondda Cynon Taf, Carmarthenshire, Rest of Wales, Glasgow, Edinburgh, Aberdeen, Lanarkshire, Rest of Scotland, Antrim, Armagh, Down, Fermanagh, Rest of Northern Ireland
Key Segments Covered Product, Indication, Distribution Channel, and Region
Key Companies Profiled Abbott; Nestlé Health Science; Danone S.A; Hormel Foods Corporation; Fresenius Kabi AG; Cipla Ltd; Eisai Co Ltd; Becton, Dickinson and Company (BD); Cook Medical Inc.; AstraZeneca Plc.; VitalStim UK; Nutricia Limited; Simply Food Solutions Limited; Ampcare, LLC; E2 Scientific Corp; TheraSIP LLC; Phagenesis; ProvaMed®; Kent Precision Foods Group
Report Coverage Future Forecast, Competition Intelligence, Key Dynamics and Challenges, Strategic Growth Initiatives

United Kingdom Dysphagia Management Industry Analysis by Category

By Product:

  • Drugs (Proton Pump Inhibitors)
  • Feeding Tubes
    • Naso-gastric Tubes
    • PEG Tubes
  • Nutritional Solutions
    • Thickeners
    • Beverages
    • Purees
  • Devices
    • Medical Cups
    • Neuromuscular Electrical Stimulation (NEMS)
    • Tactile-thermal Stimulation (TTS)
    • Pharyngeal Electrical Stimulation (PES)

By Indication:

  • Oropharyngeal Dysphagia
  • Esophageal Dysphagia

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Specialty Clinics

By Country:

  • England
  • Wales
  • Scotland
  • Northern Ireland

Frequently Asked Questions

How big is the dysphagia management business in the United Kingdom?

Total revenue is set to reach US$ 232.4 million in 2023.

What is the expected size of the target business in 2033?

The target business is expected to be valued at US$ 293.3 million by 2033.

Which product segment will witness high growth in the United Kingdom?

The drug segment is expected to witness a high CAGR of 5.2% through 2033.

What is the demand outlook for dysphagia management?

Demand in the United Kingdom is set to rise at a 2.4% CAGR through 2033.

What was the last 5 years’ CAGR for the dysphagia management business?

The target business exhibited a 1.2% CAGR from 2018 to 2022.

What is the demand outlook for England?

England will likely hold about 75.7% value share in the United Kingdom in 2033.

How many people in the United Kingdom have dysphagia?

Dysphagia affects around 4 million people in the United Kingdom.

Who is responsible for the management of dysphagia?

Speech-language pathologists, otolaryngologists, gastroenterologists, and neurologists.

Who is the treatment team for dysphagia?

Speech and language therapist, physiotherapist, occupational therapist, dietician, and nursing staff.

Table of Content

1. Executive Summary

    1.1. United Kingdom Industry Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Business Overview

    2.1. Coverage / Taxonomy

    2.2. Definition / Scope / Limitations

    2.3. Inclusion and Exclusions

3. Key Trends

    3.1. Key Trends Impacting Growth

    3.2. Innovation / Development Trends

4. Value Added Insights

    4.1. Disease Epidemiology

        4.1.1. Estimated Number of Population Suffering from Dysphagia

        4.1.2. Severity Specific Cases of Dysphagia

    4.2. International Dysphagia Diet Standardization Initiative Framework

    4.3. List of Distributors

    4.4. Regulatory Scenario

    4.5. Unmet Needs

    4.6. PESTLE Analysis

    4.7. PORTER Analysis

    4.8. Value Chain Analysis

5. Background

    5.1. Macro-Economic Factors

        5.1.1. United Kingdom GDP Growth Outlook

        5.1.2. United Kingdom Healthcare Expenditure

        5.1.3. Global Industry Analysis

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Historic Growth of Key Players

        5.2.2. Entry of Top companies

        5.2.3. Increasing Prevalence of Various Cancers

        5.2.4. Growing Geriatric Population

        5.2.5. Prevalence of Stroke and Neurological Disorders

        5.2.6. Increasing Spending on Research and Development

        5.2.7. Increasing Awareness Regarding Dysphagia

        5.2.8. Advancements in Geriatric Medicine

        5.2.9. Increasing Adoption of Home Healthcare

    5.3. Key Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Demand (in Volume) Analysis 2018 to 2022 and Forecast, 2023 to 2033

    6.1. Historical (Volume) Analysis, 2018 to 2022

    6.2. Current and Future (Volume) Projections, 2023 to 2033

        6.2.1. Y-o-Y Growth Trend Analysis

7. Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033

    7.1. Historical Value (US$ Million) Analysis, 2018 to 2022

    7.2. Current and Future Value (US$ Million) Projections, 2023 to 2033

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Pricing Analysis

    8.1. Regional Pricing Analysis By Product

    8.2. Pricing Break-up

        8.2.1. Manufacturer Level Pricing

        8.2.2. Distributor Level Pricing

    8.3. Asia Average Pricing Analysis Benchmark

    8.4. Pricing Assumptions

9. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product

    9.1. Introduction / Key Findings

    9.2. Historical Size (US$ Million) Analysis By Product, 2018 to 2022

    9.3. Current and Future Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033

        9.3.1. Drugs (Proton Pump Inhibitors)

        9.3.2. Feeding Tubes

            9.3.2.1. Naso-gastric Tubes

            9.3.2.2. PEG Tubes

        9.3.3. Nutritional Solutions

            9.3.3.1. Thickeners

            9.3.3.2. Beverages

            9.3.3.3. Purees

        9.3.4. Devices

            9.3.4.1. Medical Cups

            9.3.4.2. Neuromuscular Electrical Stimulation (NEMS)

            9.3.4.3. Tactile-thermal Stimulation (TTS)

            9.3.4.4. Pharyngeal Electrical Stimulation (PES)

    9.4. Business Attractiveness Analysis By Product

10. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    10.1. Introduction / Key Findings

    10.2. Historical Size (US$ Million) Analysis By Indication, 2018 to 2022

    10.3. Current and Future Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        10.3.1. Oropharyngeal Dysphagia

        10.3.2. Esophageal Dysphagia

    10.4. Business Attractiveness Analysis By Indication

11. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    11.3. Current and Future Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Drug Stores

        11.3.4. Specialty Clinics

    11.4. Business Attractiveness Analysis By Distribution Channel

12. Industry Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    12.1. Introduction

    12.2. Historical Size (US$ Million) Analysis By Region, 2018 to 2022

    12.3. Current and Future Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        12.3.1. England

        12.3.2. Wales

        12.3.3. Scotland

        12.3.4. Northern Ireland

    12.4. Business Attractiveness Analysis By Region

13. England Industry Analysis 2018 to 2022 and Forecast 2023 to 2033

    13.1. Introduction

    13.2. Historical Size (US$ Million) Trend Analysis By Business Taxonomy, 2018 to 2022

    13.3. Current and Future Size (US$ Million) Analysis and Forecast By Business Taxonomy, 2023 to 2033

        13.3.1. By State

            13.3.1.1. Greater London

            13.3.1.2. West Midlands

            13.3.1.3. Greater Manchester

            13.3.1.4. Yorkshire

            13.3.1.5. Rest of England

        13.3.2. By Product

        13.3.3. By Indication

        13.3.4. By Distribution Channel

    13.4. Business Attractiveness Analysis

        13.4.1. By State

        13.4.2. By Product

        13.4.3. By Indication

        13.4.4. By Distribution Channel

    13.5. Drivers and Restraints - Impact Analysis

    13.6. State Level Analysis & Forecast

        13.6.1. Greater London

            13.6.1.1. Introduction

            13.6.1.2. Industry Analysis and Forecast by Business Taxonomy

                13.6.1.2.1. By Product

                13.6.1.2.2. By Indication

                13.6.1.2.3. By Distribution Channel

        13.6.2. West Midlands

            13.6.2.1. Introduction

            13.6.2.2. Industry Analysis and Forecast by Business Taxonomy

                13.6.2.2.1. By Product

                13.6.2.2.2. By Indication

                13.6.2.2.3. By Distribution Channel

        13.6.3. Greater Manchester

            13.6.3.1. Introduction

            13.6.3.2. Industry Analysis and Forecast by Business Taxonomy

                13.6.3.2.1. By Product

                13.6.3.2.2. By Indication

                13.6.3.2.3. By Distribution Channel

        13.6.4. Yorkshire

            13.6.4.1. Introduction

            13.6.4.2. Industry Analysis and Forecast by Business Taxonomy

                13.6.4.2.1. By Product

                13.6.4.2.2. By Indication

                13.6.4.2.3. By Distribution Channel

        13.6.5. Others

            13.6.5.1. Introduction

            13.6.5.2. Industry Analysis and Forecast by Business Taxonomy

                13.6.5.2.1. By Product

                13.6.5.2.2. By Indication

                13.6.5.2.3. By Distribution Channel

14. Wales Industry Analysis 2018 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Size (US$ Million) Trend Analysis By Business Taxonomy, 2018 to 2022

    14.3. Current and Future Size (US$ Million) Analysis and Forecast By Business Taxonomy, 2023 to 2033

        14.3.1. By State

            14.3.1.1. Cardiff

            14.3.1.2. Swansea

            14.3.1.3. Rhondda Cynon Taf

            14.3.1.4. Carmarthenshire

            14.3.1.5. Rest of Wales

        14.3.2. By Product

        14.3.3. By Indication

        14.3.4. By Distribution Channel

    14.4. Business Attractiveness Analysis

        14.4.1. By State

        14.4.2. By Product

        14.4.3. By Indication

        14.4.4. By Distribution Channel

    14.5. Drivers and Restraints - Impact Analysis

    14.6. State Level Analysis & Forecast

        14.6.1. Cardiff

            14.6.1.1. Introduction

            14.6.1.2. Industry Analysis and Forecast by Business Taxonomy

                14.6.1.2.1. By Product

                14.6.1.2.2. By Indication

                14.6.1.2.3. By Distribution Channel

        14.6.2. Swansea

            14.6.2.1. Introduction

            14.6.2.2. Industry Analysis and Forecast by Business Taxonomy

                14.6.2.2.1. By Product

                14.6.2.2.2. By Indication

                14.6.2.2.3. By Distribution Channel

        14.6.3. Rhondda Cynon Taf

            14.6.3.1. Introduction

            14.6.3.2. Industry Analysis and Forecast by Business Taxonomy

                14.6.3.2.1. By Product

                14.6.3.2.2. By Indication

                14.6.3.2.3. By Distribution Channel

        14.6.4. Carmarthenshire

            14.6.4.1. Introduction

            14.6.4.2. Industry Analysis and Forecast by Business Taxonomy

                14.6.4.2.1. By Product

                14.6.4.2.2. By Indication

                14.6.4.2.3. By Distribution Channel

15. Scotland Industry Analysis 2018 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Size (US$ Million) Trend Analysis By Business Taxonomy, 2018 to 2022

    15.4. Current and Future Size (US$ Million) Analysis and Forecast By Business Taxonomy, 2023 to 2033

        15.4.1. By State

            15.4.1.1. Glasgow

            15.4.1.2. Edinburgh

            15.4.1.3. Aberdeen

            15.4.1.4. Lanarkshire

            15.4.1.5. Rest of Scotland

        15.4.2. By Product

        15.4.3. By Indication

        15.4.4. By Distribution Channel

    15.5. Business Attractiveness Analysis

        15.5.1. By State

        15.5.2. By Product

        15.5.3. By Indication

        15.5.4. By Distribution Channel

    15.6. Drivers and Restraints - Impact Analysis

    15.7. State Level Analysis & Forecast

        15.7.1. Glasgow

            15.7.1.1. Introduction

            15.7.1.2. Industry Analysis and Forecast by Business Taxonomy

                15.7.1.2.1. By Product

                15.7.1.2.2. By Indication

                15.7.1.2.3. By Distribution Channel

        15.7.2. Edinburgh

            15.7.2.1. Introduction

            15.7.2.2. Industry Analysis and Forecast by Business Taxonomy

                15.7.2.2.1. By Product

                15.7.2.2.2. By Indication

                15.7.2.2.3. By Distribution Channel

        15.7.3. Aberdeen

            15.7.3.1. Introduction

            15.7.3.2. Industry Analysis and Forecast by Business Taxonomy

                15.7.3.2.1. By Product

                15.7.3.2.2. By Indication

                15.7.3.2.3. By Distribution Channel

        15.7.4. Lanarkshire

            15.7.4.1. Introduction

            15.7.4.2. Industry Analysis and Forecast by Business Taxonomy

                15.7.4.2.1. By Product

                15.7.4.2.2. By Indication

                15.7.4.2.3. By Distribution Channel

16. North Ireland Industry Analysis 2018 to 2022 and Forecast 2023 to 2033

    16.1. Introduction

    16.2. Historical Size (US$ Million) Trend Analysis By Business Taxonomy, 2018 to 2022

    16.3. Current and Future Size (US$ Million) Analysis and Forecast By Business Taxonomy, 2023 to 2033

        16.3.1. By State

            16.3.1.1. Antrim

            16.3.1.2. Armagh

            16.3.1.3. Down

            16.3.1.4. Fermanagh

            16.3.1.5. Rest of Northern Ireland

        16.3.2. By Product

        16.3.3. By Indication

        16.3.4. By Distribution Channel

    16.4. Business Attractiveness Analysis

        16.4.1. By State

        16.4.2. By Product

        16.4.3. By Indication

        16.4.4. By Distribution Channel

    16.5. Drivers and Restraints - Impact Analysis

    16.6. State Level Analysis & Forecast

        16.6.1. Antrim

            16.6.1.1. Introduction

            16.6.1.2. Industry Analysis and Forecast by Business Taxonomy

                16.6.1.2.1. By Product

                16.6.1.2.2. By Indication

                16.6.1.2.3. By Distribution Channel

        16.6.2. Armagh

            16.6.2.1. Introduction

            16.6.2.2. Industry Analysis and Forecast by Business Taxonomy

                16.6.2.2.1. By Product

                16.6.2.2.2. By Indication

                16.6.2.2.3. By Distribution Channel

        16.6.3. Down

            16.6.3.1. Introduction

            16.6.3.2. Industry Analysis and Forecast by Business Taxonomy

                16.6.3.2.1. By Product

                16.6.3.2.2. By Indication

                16.6.3.2.3. By Distribution Channel

        16.6.4. Fermanagh

            16.6.4.1. Introduction

            16.6.4.2. Industry Analysis and Forecast by Business Taxonomy

                16.6.4.2.1. By Product

                16.6.4.2.2. By Indication

                16.6.4.2.3. By Distribution Channel

17. Structure Analysis

    17.1. Industry Analysis by Tier of Companies

    17.2. Business Share Analysis of Top Players

    17.3. Presence Analysis

        17.3.1. Regional footprint of Players

        17.3.2. Product Footprint by Players

        17.3.3. Channel footprint by Players

18. Competition Analysis

    18.1. Competition Benchmarking

    18.2. Branding and Promotional Strategies, By Key Players

    18.3. Competition Dashboard

    18.4. Key Development Analysis

    18.5. Competition Deep Dive

        18.5.1. Abbott

            18.5.1.1. Overview

            18.5.1.2. Product Portfolio

            18.5.1.3. Key Financials

            18.5.1.4. Sales Footprint

            18.5.1.5. SWOT Analysis

            18.5.1.6. Key Developments

            18.5.1.7. Strategy Overview

                18.5.1.7.1. Channel Strategy

                18.5.1.7.2. Product Strategy

                18.5.1.7.3. Business Strategy

        18.5.2. Kent Precision Foods Group

            18.5.2.1. Overview

            18.5.2.2. Product Portfolio

            18.5.2.3. Key Financials

            18.5.2.4. Sales Footprint

            18.5.2.5. SWOT Analysis

            18.5.2.6. Key Developments

            18.5.2.7. Strategy Overview

                18.5.2.7.1. Channel Strategy

                18.5.2.7.2. Product Strategy

                18.5.2.7.3. Business Strategy

        18.5.3. Nestlé Health Science

            18.5.3.1. Overview

            18.5.3.2. Product Portfolio

            18.5.3.3. Key Financials

            18.5.3.4. Sales Footprint

            18.5.3.5. SWOT Analysis

            18.5.3.6. Key Developments

            18.5.3.7. Strategy Overview

                18.5.3.7.1. Channel Strategy

                18.5.3.7.2. Product Strategy

                18.5.3.7.3. Business Strategy

        18.5.4. Danone S.A

            18.5.4.1. Overview

            18.5.4.2. Product Portfolio

            18.5.4.3. Key Financials

            18.5.4.4. Sales Footprint

            18.5.4.5. SWOT Analysis

            18.5.4.6. Key Developments

            18.5.4.7. Strategy Overview

                18.5.4.7.1. Channel Strategy

                18.5.4.7.2. Product Strategy

                18.5.4.7.3. Business Strategy

        18.5.5. Hormel Foods Corporation

            18.5.5.1. Overview

            18.5.5.2. Product Portfolio

            18.5.5.3. Key Financials

            18.5.5.4. Sales Footprint

            18.5.5.5. SWOT Analysis

            18.5.5.6. Key Developments

            18.5.5.7. Strategy Overview

                18.5.5.7.1. Channel Strategy

                18.5.5.7.2. Product Strategy

                18.5.5.7.3. Business Strategy

        18.5.6. Fresenius Kabi AG

            18.5.6.1. Overview

            18.5.6.2. Product Portfolio

            18.5.6.3. Key Financials

            18.5.6.4. Sales Footprint

            18.5.6.5. SWOT Analysis

            18.5.6.6. Key Developments

            18.5.6.7. Strategy Overview

                18.5.6.7.1. Channel Strategy

                18.5.6.7.2. Product Strategy

                18.5.6.7.3. Business Strategy

        18.5.7. Cipla Ltd

            18.5.7.1. Overview

            18.5.7.2. Product Portfolio

            18.5.7.3. Key Financials

            18.5.7.4. Sales Footprint

            18.5.7.5. SWOT Analysis

            18.5.7.6. Key Developments

            18.5.7.7. Strategy Overview

                18.5.7.7.1. Channel Strategy

                18.5.7.7.2. Product Strategy

                18.5.7.7.3. Business Strategy

        18.5.8. Eisai Co Ltd

            18.5.8.1. Overview

            18.5.8.2. Product Portfolio

            18.5.8.3. Key Financials

            18.5.8.4. Sales Footprint

            18.5.8.5. SWOT Analysis

            18.5.8.6. Key Developments

            18.5.8.7. Strategy Overview

                18.5.8.7.1. Channel Strategy

                18.5.8.7.2. Product Strategy

                18.5.8.7.3. Business Strategy

        18.5.9. Becton, Dickinson and Company (BD)

            18.5.9.1. Overview

            18.5.9.2. Product Portfolio

            18.5.9.3. Key Financials

            18.5.9.4. Sales Footprint

            18.5.9.5. SWOT Analysis

            18.5.9.6. Key Developments

            18.5.9.7. Strategy Overview

                18.5.9.7.1. Channel Strategy

                18.5.9.7.2. Product Strategy

                18.5.9.7.3. Business Strategy

        18.5.10. Cook Medical Inc.

            18.5.10.1. Overview

            18.5.10.2. Product Portfolio

            18.5.10.3. Key Financials

            18.5.10.4. Sales Footprint

            18.5.10.5. SWOT Analysis

            18.5.10.6. Key Developments

            18.5.10.7. Strategy Overview

                18.5.10.7.1. Channel Strategy

                18.5.10.7.2. Product Strategy

                18.5.10.7.3. Business Strategy

        18.5.11. AstraZeneca Plc.

            18.5.11.1. Overview

            18.5.11.2. Product Portfolio

            18.5.11.3. Key Financials

            18.5.11.4. Sales Footprint

            18.5.11.5. SWOT Analysis

            18.5.11.6. Key Developments

            18.5.11.7. Strategy Overview

                18.5.11.7.1. Channel Strategy

                18.5.11.7.2. Product Strategy

                18.5.11.7.3. Business Strategy

        18.5.12. VitalStim UK

            18.5.12.1. Overview

            18.5.12.2. Product Portfolio

            18.5.12.3. Key Financials

            18.5.12.4. Sales Footprint

            18.5.12.5. SWOT Analysis

            18.5.12.6. Key Developments

            18.5.12.7. Strategy Overview

                18.5.12.7.1. Channel Strategy

                18.5.12.7.2. Product Strategy

                18.5.12.7.3. Business Strategy

        18.5.13. Nutricia Limited

            18.5.13.1. Overview

            18.5.13.2. Product Portfolio

            18.5.13.3. Key Financials

            18.5.13.4. Sales Footprint

            18.5.13.5. SWOT Analysis

            18.5.13.6. Key Developments

            18.5.13.7. Strategy Overview

                18.5.13.7.1. Channel Strategy

                18.5.13.7.2. Product Strategy

                18.5.13.7.3. Business Strategy

        18.5.14. Simply Food Solutions Limited

            18.5.14.1. Overview

            18.5.14.2. Product Portfolio

            18.5.14.3. Key Financials

            18.5.14.4. Sales Footprint

            18.5.14.5. SWOT Analysis

            18.5.14.6. Key Developments

            18.5.14.7. Strategy Overview

                18.5.14.7.1. Channel Strategy

                18.5.14.7.2. Product Strategy

                18.5.14.7.3. Business Strategy

        18.5.15. Ampcare, LLC

            18.5.15.1. Overview

            18.5.15.2. Product Portfolio

            18.5.15.3. Key Financials

            18.5.15.4. Sales Footprint

            18.5.15.5. SWOT Analysis

            18.5.15.6. Key Developments

            18.5.15.7. Strategy Overview

                18.5.15.7.1. Channel Strategy

                18.5.15.7.2. Product Strategy

                18.5.15.7.3. Business Strategy

        18.5.16. E2 Scientific Corp

            18.5.16.1. Overview

            18.5.16.2. Product Portfolio

            18.5.16.3. Key Financials

            18.5.16.4. Sales Footprint

            18.5.16.5. SWOT Analysis

            18.5.16.6. Key Developments

            18.5.16.7. Strategy Overview

                18.5.16.7.1. Channel Strategy

                18.5.16.7.2. Product Strategy

                18.5.16.7.3. Business Strategy

        18.5.17. TheraSIP LLC

            18.5.17.1. Overview

            18.5.17.2. Product Portfolio

            18.5.17.3. Key Financials

            18.5.17.4. Sales Footprint

            18.5.17.5. SWOT Analysis

            18.5.17.6. Key Developments

            18.5.17.7. Strategy Overview

                18.5.17.7.1. Channel Strategy

                18.5.17.7.2. Product Strategy

                18.5.17.7.3. Business Strategy

        18.5.18. Phagenesis

            18.5.18.1. Overview

            18.5.18.2. Product Portfolio

            18.5.18.3. Key Financials

            18.5.18.4. Sales Footprint

            18.5.18.5. SWOT Analysis

            18.5.18.6. Key Developments

            18.5.18.7. Strategy Overview

                18.5.18.7.1. Channel Strategy

                18.5.18.7.2. Product Strategy

                18.5.18.7.3. Business Strategy

        18.5.19. ProvaMed®

            18.5.19.1. Overview

            18.5.19.2. Product Portfolio

            18.5.19.3. Key Financials

            18.5.19.4. Sales Footprint

            18.5.19.5. SWOT Analysis

            18.5.19.6. Key Developments

            18.5.19.7. Strategy Overview

                18.5.19.7.1. Channel Strategy

                18.5.19.7.2. Product Strategy

                18.5.19.7.3. Business Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Neurostimulation Market

March 2018

REP-GB-400

October 2023

333 pages

Healthcare

Throat Sprays Market

August 2022

REP-GB-15391

June 2023

324 pages

Healthcare

Proton Pump Inhibitors Market

June 2023

REP-GB-17480

290 pages

Healthcare

Enteral Feeding Devices Market

August 2020

REP-GB-12403

January 2023

322 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Dysphagia Management Industry Analysis in the United Kingdom